Masimo (MASI) Q4 2025 earnings review
Danaher Acquisition Caps a Dramatic Turnaround Year
Masimo will be acquired by Danaher for $180/share in cash, concluding a tumultuous period marked by activist intervention, the ouster of its founder, and the costly divestiture of its consumer audio business. Operationally, Masimo engineered a massive profitability turnaround in FY25. Healthcare revenue accelerated to 12% YoY growth in Q4 ($412.5M), while full-year GAAP operating margin reversed from 4.5% to 20.3%. The return to a pure-play medtech focus, strict cost discipline, and robust contracting momentum successfully positioned the company for this premium exit, though the legacy of the consumer misstep resulted in a $151.5M GAAP net loss for the year.
🐂 Bull Case
The $180/share all-cash acquisition by Danaher offers immediate, certain value to shareholders, removing the execution risk of Masimo's long-term standalone plan.
Stripped of the Sound United distraction, the core healthcare business generated $1.52B in FY25 (+9.4% YoY), with Q4 revenue growth accelerating to 12%. Technology board shipments reached 270,600 units for the year.
🐻 Bear Case
If the Danaher deal faces antitrust hurdles, Masimo falls back on a standalone thesis heavily burdened by DOJ subpoenas, an SEC accounting probe, and toxic arbitration with former CEO Joe Kiani's entity, Willow.
While operating margins recovered, the divestiture of Sound United incurred a severe $359.2M discontinued operations loss, dragging FY25 GAAP net income to negative $151.5M and proving the ultimate cost of the consumer misadventure.
⚖️ Verdict: 🟢
Bullish (Merger Arbitrage). The operational turnaround is highly impressive, with accelerating revenue and structurally repaired margins. The Danaher acquisition validates the value of Masimo's core SET pulse oximetry franchise.
Key Themes
The Danaher Acquisition
On February 16, 2026, Masimo entered a definitive agreement to be acquired by Danaher for $180 per share in cash. This fundamentally shifts the investment thesis from a standalone turnaround to a merger completion play. The deal validates the activist (Politan) thesis that Masimo's core healthcare assets were drastically undervalued while burdened by the consumer audio business.
Cost Structure Radically Optimized
Reversing the bloat of the previous regime, operating margin expanded dramatically. SG&A dropped from 39.3% of revenue in FY24 to 33.1% in FY25, while R&D fell from 13.1% to 8.3%. This lean profile proves the underlying cash-generation power of the razor/razorblade sensor model when corporate overhead is controlled.
Installed Base Growth Remains Stable
Shipments of technology boards and instruments are the leading indicator for future high-margin sensor revenue. The trajectory remained stable and healthy throughout the year, culminating in ~69,000 shipments in Q4 and 270,600 for the full year (+15% YoY).
Legal and Regulatory Exposure Mounting
A specific, major concern contradicting the clean 'fresh start' narrative is the explosion of legal issues. The DOJ issued subpoenas and a civil investigative demand under the False Claims Act regarding a delayed Rad-G product recall. Simultaneously, the SEC subpoenaed the company over accounting irregularity allegations from a former employee. While Danaher assumes these risks, they represent significant standalone liabilities if the deal breaks.
The Kiani / Willow Fallout
The separation from founder Joe Kiani is highly combative. Kiani is suing for a $35M 'Special Payment' and millions in stock, while Masimo is suing him for fiduciary breach and seeking Section 16(b) short-swing profit disgorgement from his allies. Furthermore, Willow (controlled by Kiani) initiated arbitration demanding up to $27M in disputed royalties and claiming Masimo breached the critical Cross-Licensing Agreement covering the rainbow technology.
Tariff and Macro Supply Chain Risks
Despite successfully mitigating >50% of the initial $33M-$37M tariff hit in 2025, macroeconomic trade policy remains a headwind. Management explicitly noted that 25% of healthcare COGS is sourced from Mexico and highly vulnerable to shifting U.S. trade policies, while imported components from China continue to face high duties.
Next-Gen AI & Advanced Parameters
Beyond core pulse oximetry, Masimo's 'Wave 2' growth strategy relies on AI-powered algorithms. The imminent rollout of the OIRD (Opioid-Induced Respiratory Depression) algorithm and planned 2026 launches of AFib detection via pulse ox sensor provide concrete paths to cross-sell into the existing installed base and capture the $2.5B advanced monitoring market.
Other KPIs
Accelerating from $162.5M in FY24. This reflects the improved profitability of the core healthcare business and tighter working capital management, easily covering $19.4M in CapEx.
The final financial toll of the Sound United consumer audio business. This includes massive intangible asset impairment charges recognized as the company marked the unit down to its $350M sale price.
Before the Danaher deal was announced, Masimo aggressively deployed cash from the Sound United divestiture to buy back 2.5 million shares at an average price of $146.91, proving highly accretive given the $180 takeout price.
Guidance
Stable. Outlined during the January JPM presentation, this target represents normalized growth for the pure-play healthcare business, driven by standard pricing leverage, core pulse ox conversions, and new product introductions.
Accelerating. Management projected further scaling of the business to reach ~30% operating margins by 2028, up from 20.3% in FY25. Note: All standalone guidance is now functionally superseded by the pending Danaher acquisition.
Key Questions
Merger Regulatory Hurdles
Given Danaher's existing footprint in life sciences and diagnostics, what specific product overlaps could draw FTC or international antitrust scrutiny during the HSR review process?
Willow IP Risk Transfer
How does the pending arbitration with Willow over the Cross-Licensing Agreement impact the Danaher deal? Does Danaher have specific walk-away rights if Willow successfully revokes the rainbow technology license?
DOJ Investigation Scope
Can you quantify the potential liability surrounding the DOJ's False Claims Act civil investigative demand regarding the Rad-G recall? How deeply does this penetrate historical billing practices?